Switzerland: VectivBio prices follow-on and private placement with Forbion

Nasdaq listed VectivBio Holding, a clinical-stage biopharmaceutical company, has announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a price of US$5.25 per share to raise aggregate gross proceeds of approximately US$30m. In addition to the ordinary shares sold in the public offering, VectivBio has entered into a subscription and share…

You must be a HMI Subscriber to view this content.

Subscribe Now »